Takeda Pharmaceutical (TAK) Invested Capital (2018 - 2026)

Takeda Pharmaceutical's Invested Capital history runs 9 years deep, the most recent figure standing at $53.2 billion for Q1 2026.

• In Q1 2026, Invested Capital fell 29.1% year-over-year to $53.2 billion; the TTM figure through Mar 2026 stood at $53.2 billion (down 29.1% YoY), while the FY2026 annual figure was $55.4 billion, down 26.25% from the prior year.
• Invested Capital was $53.2 billion for Q1 2026 at Takeda Pharmaceutical, roughly flat from $53.4 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $86.3 billion in Q1 2022 to a low of $3.7 billion in Q3 2024.
• Historically, Invested Capital has averaged $56.1 billion across 5 years, with a median of $52.9 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Invested Capital sank 92.93% in 2024, then surged 1292.34% in 2025.
• A 5-year view of Invested Capital shows it stood at $47.3 billion in 2022, then climbed by 4.23% to $49.3 billion in 2023, then rose by 6.91% to $52.7 billion in 2024, then climbed by 1.28% to $53.4 billion in 2025, then retreated by 0.27% to $53.2 billion in 2026.
• The last three Invested Capital figures came in at $53.2 billion (Q1 2026), $53.4 billion (Q4 2025), and $52.1 billion (Q3 2025), per Business Quant data.